Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company’s web site at www.palatin.com.
- 16 years ago
QualityStocks
Palatin Technologies, Inc. (AMEX: PTN)
Tags Rodman & Renshaw
Related Post
-
D-Wave Quantum Inc. (NYSE: QBTS) Expands Quantum Optimization Offerings to Accelerate Commercial Adoption
At its Qubits 2025 user conference, D-Wave introduced new hybrid solver capabilities supporting continuous variables…
-
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
An increase in deaths from COVID-19 underscores the persistent danger of the virus and the…
-
Thumzup Media Corp. (NASDAQ: TZUP) Continues Building Its Client Base with Its Proprietary Tech for Ad Campaigns
Social media commerce is expected to grow to $821 billion in 2025[1], demonstrating its importance…